Ind-Swift Laboratories Limited (INDSWFTLAB.NS)
INR 83.83
(1.35%)
INR 83.83
(1.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2 Billion INR | 10.68% |
| 2022 | 1.81 Billion INR | 96.4% |
| 2021 | 924.22 Million INR | -16.71% |
| 2020 | 1.1 Billion INR | 50.03% |
| 2019 | 739.59 Million INR | 66.24% |
| 2018 | 444.89 Million INR | -6.18% |
| 2017 | 474.2 Million INR | 181.26% |
| 2016 | -583.58 Million INR | 31.66% |
| 2015 | -853.91 Million INR | 40.98% |
| 2014 | -1.44 Billion INR | -0.45% |
| 2013 | -1.44 Billion INR | -11.05% |
| 2012 | -1.29 Billion INR | -175.64% |
| 2011 | 1.71 Billion INR | 17.76% |
| 2010 | 1.45 Billion INR | 46.32% |
| 2009 | 995.26 Million INR | -0.2% |
| 2008 | 997.27 Million INR | 36.08% |
| 2007 | 732.83 Million INR | 43.41% |
| 2006 | 511.01 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -99.9 Million INR | 100.0% |
| 2023 Q2 | 599.04 Million INR | 29.06% |
| 2023 Q1 | 464.14 Million INR | -28.15% |
| 2023 FY | 2 Billion INR | 10.68% |
| 2023 Q4 | -499.74 Million INR | -210.45% |
| 2023 Q3 | 452.48 Million INR | -24.47% |
| 2022 Q3 | 467.31 Million INR | -6.33% |
| 2022 Q1 | 367.27 Million INR | 192.87% |
| 2022 FY | 1.81 Billion INR | 96.4% |
| 2022 Q4 | 645.96 Million INR | 38.23% |
| 2022 Q2 | 498.9 Million INR | 35.84% |
| 2021 Q2 | 492.94 Million INR | 32.55% |
| 2021 FY | 924.22 Million INR | -16.71% |
| 2021 Q1 | 371.88 Million INR | 171.55% |
| 2021 Q3 | 395.38 Million INR | -19.79% |
| 2021 Q4 | -395.48 Million INR | -200.03% |
| 2020 Q1 | 236.86 Million INR | -14.29% |
| 2020 FY | 1.1 Billion INR | 50.03% |
| 2020 Q4 | 136.94 Million INR | -52.13% |
| 2020 Q3 | 286.1 Million INR | -3.07% |
| 2020 Q2 | 295.15 Million INR | 24.61% |
| 2019 Q3 | 121.96 Million INR | 164.84% |
| 2019 FY | 739.59 Million INR | 66.24% |
| 2019 Q1 | 89.85 Million INR | -0.17% |
| 2019 Q2 | 46.05 Million INR | -48.75% |
| 2019 Q4 | 276.35 Million INR | 126.59% |
| 2018 Q3 | 98.74 Million INR | 74.18% |
| 2018 FY | 444.89 Million INR | -6.18% |
| 2018 Q4 | 90 Million INR | -8.85% |
| 2018 Q2 | 56.69 Million INR | 12.31% |
| 2018 Q1 | 50.47 Million INR | 0.0% |
| 2017 FY | 474.2 Million INR | 181.26% |
| 2016 FY | -583.58 Million INR | 31.66% |
| 2015 FY | -853.91 Million INR | 40.98% |
| 2014 FY | -1.44 Billion INR | -0.45% |
| 2013 FY | -1.44 Billion INR | -11.05% |
| 2012 Q4 | 71.32 Million INR | -58.53% |
| 2012 Q3 | 172.02 Million INR | -3.4% |
| 2012 Q1 | -215.03 Million INR | 0.0% |
| 2012 Q2 | 178.07 Million INR | 182.81% |
| 2012 FY | -1.29 Billion INR | -175.64% |
| 2011 FY | 1.71 Billion INR | 17.76% |
| 2010 FY | 1.45 Billion INR | 46.32% |
| 2009 FY | 995.26 Million INR | -0.2% |
| 2008 FY | 997.27 Million INR | 36.08% |
| 2007 FY | 732.83 Million INR | 43.41% |
| 2006 FY | 511.01 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 65.109% |
| Hester Biosciences Limited | 364.77 Million INR | -450.767% |
| Aarti Drugs Limited | 7.14 Billion INR | 71.897% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 35.775% |
| Albert David Limited | 1.33 Billion INR | -50.551% |
| Alembic Limited | 767.77 Million INR | -161.671% |
| Alkem Laboratories Limited | 19.46 Billion INR | 89.677% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -745.336% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -9626.147% |
| Brooks Laboratories Limited | -72.25 Million INR | 2880.592% |
| Eris Lifesciences Limited | 5.18 Billion INR | 61.228% |
| FDC Limited | 3.03 Billion INR | 33.777% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 77.626% |
| Gufic Biosciences Limited | 2.89 Billion INR | 30.575% |
| Hikal Limited | 1.49 Billion INR | -34.455% |
| Ind-Swift Limited | 1.22 Billion INR | -63.874% |
| Innova Captab Limited | 2.53 Billion INR | 20.698% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 59.349% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -838.625% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 61.283% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -5.388% |
| Lupin Limited | 27.75 Billion INR | 92.762% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -7216.749% |
| Medico Remedies Limited | 277.11 Million INR | -624.974% |
| Morepen Laboratories Limited | 4.17 Billion INR | 51.866% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 48.362% |
| Orchid Pharma Limited | 2.36 Billion INR | 14.91% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 27.888% |
| RPG Life Sciences Limited | 2.29 Billion INR | 12.357% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -865.649% |
| Sigachi Industries Limited | 1.47 Billion INR | -36.308% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 152.143% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 56.398% |
| Themis Medicare Limited | 1.3 Billion INR | -54.173% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Vaishali Pharma Limited | 6.29 Million INR | -31819.813% |
| Wanbury Limited | 1.7 Billion INR | -17.68% |
| Windlas Biotech Limited | 1.29 Billion INR | -54.673% |
| ZIM Laboratories Limited | 1.09 Billion INR | -82.953% |
| Ipca Laboratories Limited | 29.59 Billion INR | 93.212% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.074% |
| Venus Remedies Limited | 534.65 Million INR | -275.765% |
| Sakar Healthcare Limited | 495.5 Million INR | -305.451% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 98.078% |
| Divi's Laboratories Limited | 18.31 Billion INR | 89.028% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 55.094% |
| Mankind Pharma Limited | 40.86 Billion INR | 95.084% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Laurus Labs Limited | 3.94 Billion INR | 49.12% |
| Neuland Laboratories Limited | 5.31 Billion INR | 62.223% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 73.361% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 69.103% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 95.574% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -223.502% |
| Wockhardt Limited | 140 Million INR | -1335.024% |
| Bal Pharma Limited | 214.56 Million INR | -836.311% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 97.034% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -63.203% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -264.226% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 72.194% |
| Shilpa Medicare Limited | 3.76 Billion INR | 46.591% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 89.79% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -70869.851% |
| Granules India Limited | 6.52 Billion INR | 69.226% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -706.028% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 92.07% |
| NATCO Pharma Limited | 25.96 Billion INR | 92.262% |
| Suven Life Sciences Limited | -1.22 Billion INR | 263.893% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 61.556% |
| Indoco Remedies Limited | 1.52 Billion INR | -31.792% |
| Alpa Laboratories Limited | 61.51 Million INR | -3165.924% |
| Lasa Supergenerics Limited | -458 Million INR | 538.649% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 148.822% |